Immunogen, Inc. (IMGN) SEC Filing 8-K Material Event for the period ending Monday, September 30, 2019

Immunogen Inc

CIK: 855654 Ticker: IMGN

View differences made from one to another to evaluate Immunogen Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Immunogen Inc.


Assess how Immunogen Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Immunogen Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Immunogen Inc provided additional information to their SEC Filing as exhibits

Ticker: IMGN
CIK: 855654
Form Type: 8-K Corporate News
Accession Number: 0001558370-19-008729
Submitted to the SEC: Mon Sep 30 2019 8:08:17 AM EST
Accepted by the SEC: Mon Sep 30 2019
Period: Monday, September 30, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events
  3. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: